| Identification | Back Directory | [Name]
Leronlimab | [CAS]
674782-26-4 | [Synonyms]
Leronlimab
Research Grade Leronlimab
Research Grade Leronlimab(DHE85401) |
| Hazard Information | Back Directory | [Uses]
Leronlimab (PRO 140) is a humanized IgG4 anti-CCR5 monoclonal antibody. Leronlimab inhibits CCR5-mediated HIV-1 viral and lung metastasis in mouse tumor models. Leronlimab can be used for the research of HIV nonalcoholic steatohepatitis (NASH) and cancer[1]. | [in vivo]
Leronlimab (2 mg; i.p., twice a week) reduces lung metastasis in murine xenograft models[1]. | Animal Model: | Female NCI Athymic nu/nu nude mice with MB-MDA-231 cells expressing Luc2-eGFP injection[1] | | Dosage: | 2 mg | | Administration: | Intraperitoneal injection; 2 mg, twice a week | | Result: | Reduced the volume of pulmonary metastases at 8 weeks. |
| [References]
[1] Jiao X, et al. Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy. Breast Cancer Res. 2021 Jan 23;23(1):11. DOI:10.1186/s13058-021-01391-1 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
18108604356 18108604356 |
| Website: |
www.biolabreagent.com/ |
|